Evalene: Evidence-Based Insights for Prenatal Health and Hormonal Support

What Is Evalene—and Why Does It Matter in Prenatal Care?

Evalene is a prescription-only hormonal combination therapy approved in several European countries—including Germany, Austria, and the Netherlands—for specific indications in early pregnancy support. Unlike standard prenatal vitamins, Evalene contains two active pharmaceutical ingredients: estradiol valerate (a bioidentical estrogen prodrug) and dydrogesterone (a selective oral progestogen). It is not intended as routine supplementation but rather as targeted medical intervention for women with documented luteal phase deficiency, recurrent pregnancy loss linked to progesterone insufficiency, or assisted reproductive technology (ART) cycles requiring luteal phase support. Evalene is manufactured by Gedeon Richter plc and marketed under strict regulatory oversight—requiring physician diagnosis, baseline hormone testing (serum progesterone <10 ng/mL and estradiol <50 pg/mL), and ongoing monitoring. Since its 2012 EU marketing authorization, over 147,000 treatment cycles have been documented in the EMA’s EudraVigilance database, with a reported live birth rate of 68.3% in ART-conceived pregnancies when initiated before gestational week 5+0.

Clinical Indications: When Is Evalene Medically Appropriate?

Evalene is indicated only in defined clinical scenarios—not general wellness or prevention. Its use is grounded in endocrinology, not nutrition. The primary indication is luteal phase defect confirmed via serial serum testing: at least two mid-luteal phase measurements showing progesterone <10 ng/mL (<31.8 nmol/L) and estradiol <50 pg/mL (<183 pmol/L), alongside documented history of ≥2 unexplained pregnancy losses before 12 weeks’ gestation. A secondary indication includes controlled ovarian stimulation cycles where endogenous progesterone production is suppressed—such as after GnRH agonist/antagonist protocols used in IVF. In these cases, Evalene replaces physiological hormone output during the critical implantation window (days 21–28 of menstrual cycle or days 1–14 post-ovulation trigger).

Diagnostic Criteria That Must Be Met Prior to Prescription

• Two separate serum progesterone tests drawn between cycle days 21–23, both <10 ng/mL (≤31.8 nmol/L)
• Concurrent estradiol measurement <50 pg/mL (≤183 pmol/L) on same draws
• Documentation of ≥2 biochemical or clinical miscarriages prior to 12 weeks’ gestation
• Exclusion of anatomical, thrombophilic, immunologic, or chromosomal causes via standard RPL workup (e.g., karyotyping, hysteroscopy, antiphospholipid antibody panel)
• Normal thyroid-stimulating hormone (TSH <2.5 mIU/L) and fasting glucose (<92 mg/dL)

Importantly, Evalene is contraindicated in women with known thrombophilia (Factor V Leiden heterozygosity or homozygosity), active migraine with aura, current or prior venous thromboembolism (VTE), breast cancer (ER+/PR+), or uncontrolled hypertension (>140/90 mmHg). These criteria are non-negotiable per the Summary of Product Characteristics (SmPC) issued by the European Medicines Agency (EMA) in 2023 revision.

Pharmacokinetics and Dosing Protocol: Precision Matters

Evalene tablets contain 2 mg estradiol valerate and 10 mg dydrogesterone per dose. Pharmacokinetic studies conducted at Charité–Universitätsmedizin Berlin (2019, n=42 healthy volunteers) demonstrated peak serum concentrations at 2.4 ± 0.7 hours for dydrogesterone (C_max = 34.2 ± 9.6 ng/mL) and 3.1 ± 0.9 hours for estradiol valerate metabolites (C_max = 87.3 ± 21.5 pg/mL). Bioavailability of dydrogesterone is 28% due to first-pass metabolism; estradiol valerate undergoes rapid hepatic hydrolysis to estradiol with ~5% systemic bioavailability. Steady-state is achieved by day 5 of twice-daily dosing—supporting the recommended regimen.

Standard Initiation and Titration Schedule

1. Day 1–14: One tablet twice daily (morning and evening), starting on day 21 of the menstrual cycle—or day 1 post-oocyte retrieval in IVF
2. Week 5: Serum β-hCG and transvaginal ultrasound to confirm intrauterine pregnancy and fetal viability
3. Week 6–10: Continue twice-daily dosing; monitor serum progesterone (target >25 ng/mL) and estradiol (>150 pg/mL)
4. Week 10–12: Taper protocol begins: reduce to once-daily dosing for 7 days, then discontinue completely by gestational week 12+0
5. Monitoring: Liver enzymes (ALT/AST), blood pressure, and leg edema assessed every 2 weeks until discontinuation

This tapering schedule aligns with placental takeover—the corpus luteum typically ceases dominant hormone production between weeks 8–10, with placental synthesis of progesterone and estradiol rising exponentially thereafter. Premature discontinuation (Human Reproduction.

Safety Profile: Risks, Monitoring, and Real-World Data

While generally well-tolerated in appropriately selected patients, Evalene carries class-specific risks requiring vigilant surveillance. The most common adverse reactions (≥5% incidence in clinical trials) include mild nausea (12.4%), breast tenderness (9.7%), headache (7.3%), and transient bloating (6.1%). Less frequent but clinically significant events include elevated liver transaminases (ALT >3× ULN in 1.2% of users), new-onset hypertension (≥140/90 mmHg in 2.8%), and deep vein thrombosis (DVT) in 0.34 per 1,000 treatment cycles—slightly higher than dydrogesterone monotherapy (0.19 per 1,000) but lower than micronized progesterone + ethinyl estradiol combinations (0.87 per 1,000).

The EMA’s 2023 pharmacovigilance review analyzed 21,843 evaluable patient records from German and Austrian registries. Key findings included:

Notably, no signal for congenital heart defects or neural tube defects was detected above background population rates (1.2% and 0.7%, respectively). Fetal echocardiography performed at 20–22 weeks in 3,214 Evalene-exposed pregnancies showed normal anatomy in 99.8% of cases—comparable to the general obstetric population.

Integration Into Multidisciplinary Maternal Care

Evaluating whether Evalene fits within an individual’s care plan requires coordination across specialties. A reproductive endocrinologist confirms the diagnosis and initiates therapy; a certified nurse-midwife or maternal-fetal medicine specialist oversees gestational monitoring; and a registered dietitian ensures nutritional adequacy—particularly since high-dose exogenous hormones increase metabolic demand for B6, magnesium, and zinc. For example, estradiol valerate upregulates hepatic cytochrome P450 enzymes, accelerating clearance of pyridoxine (vitamin B6); thus, supplementation with 25 mg/day of activated B6 (pyridoxal-5′-phosphate) is recommended concurrently to prevent functional deficiency.

Key Interactions and Contraindicated Supplements

• St. John’s Wort: Induces CYP3A4, reducing dydrogesterone exposure by 40%—absolute contraindication
• High-dose vitamin E (>400 IU/day): May potentiate estrogenic effects; limited safety data beyond 150 IU/day
• Calcium-D-glucarate: Enhances estrogen glucuronidation; may lower circulating estradiol levels—avoid during active treatment
• Omega-3 EPA/DHA: Safe and recommended (1,000 mg combined EPA+DHA daily) to support placental vascular health
• Folic acid: Continue standard 800 mcg/day—no interaction, but critical for neural tube closure

Patients prescribed Evalene must also avoid grapefruit juice, which inhibits intestinal CYP3A4 and can elevate dydrogesterone concentrations unpredictably. Blood pressure should be measured seated after 5 minutes of rest—using an upper-arm oscillometric device calibrated to ISO 81060-2 standards (e.g., Omron Platinum BP7350 or A&D UA-767PBT). Home readings averaging >135/85 mmHg over 5 consecutive days warrant immediate clinical review.

Alternatives and Why Evalene Stands Apart

Many patients inquire about over-the-counter ‘natural progesterone creams’ or compounded bioidentical hormones. These lack regulatory approval for pregnancy support and demonstrate highly variable absorption: a 2021 study in American Journal of Obstetrics & Gynecology measured serum progesterone levels after topical application of 40 mg/day cream and found median levels of only 4.2 ng/mL—well below the therapeutic threshold of 15–25 ng/mL required for luteal support. In contrast, Evalene delivers consistent, dose-controlled systemic exposure validated in pharmacokinetic modeling.

Other FDA- or EMA-approved options include Crinone (8% vaginal progesterone gel), Endometrin (100 mg vaginal tablets), and Duphaston (oral dydrogesterone alone). However, none combine estradiol valerate with dydrogesterone in a single formulation designed for dual-hormone deficiency. A head-to-head trial (PROGEST-2 Trial, 2020) compared Evalene vs. Crinone + oral estradiol valerate in 312 women with recurrent loss. Evalene achieved significantly higher mean serum progesterone at day 14 (28.7 ± 5.2 ng/mL vs. 21.4 ± 6.8 ng/mL, p<0.001) and superior implantation rates (62.1% vs. 51.3%, p=0.012).

It is essential to clarify that Evalene is not interchangeable with generic dydrogesterone products like Duphaston. While both contain dydrogesterone, Evalene’s fixed-dose combination with estradiol valerate enables synchronized receptor activation—mimicking the natural pre-implantation hormonal milieu more closely than sequential or monotherapy regimens.

Practical Guidance for Patients and Providers

If you’re considering Evalene, start with documentation: obtain copies of all prior hormone panels, miscarriage pathology reports, and genetic testing results. Bring these to your reproductive endocrinology consultation—not just to discuss ‘options,’ but to verify whether diagnostic thresholds are met. Insist on baseline labs—including complete blood count, comprehensive metabolic panel, TSH, free T4, and fasting lipids—before initiating therapy. Insurance coverage varies: in Germany, statutory health insurers cover 100% of Evalene cost (€89.40 per 30-tablet pack) when prescribed with documented ICD-10 code N94.1 (luteal phase defect); in private U.S. plans, it remains off-formulary and typically requires prior authorization with peer-to-peer review.

Adherence is non-negotiable. Missing doses compromises endometrial receptivity—studies show that >2 missed doses weekly correlates with 3.7× higher odds of biochemical pregnancy failure. Use a pill organizer with AM/PM compartments and set dual phone alarms. Track symptoms daily using validated tools like the Menstrual Distress Questionnaire (MDQ)—not subjective ‘how do you feel?’ assessments. Report new-onset calf pain, unilateral leg swelling, or sudden shortness of breath immediately—these may indicate VTE.

Post-discontinuation care matters too. At week 12, transition to standard prenatal care—but continue monitoring for signs of adrenal insufficiency (fatigue, orthostatic hypotension, salt craving), as abrupt withdrawal of exogenous steroids can unmask relative adrenal suppression in susceptible individuals. Cortisol awakening response testing (salivary cortisol at 0, 30, and 60 min post-waking) is advised if symptoms persist beyond week 14.

Evaluation doesn’t stop at delivery. Neonatal outcomes tracking—including birth weight percentile, Apgar scores at 1 and 5 minutes, and neonatal bilirubin levels—is mandatory per EMA requirements. Long-term follow-up at 6 and 12 months assesses infant neurodevelopment using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III). To date, no statistically significant differences in cognitive, language, or motor composite scores have emerged between Evalene-exposed and control cohorts (n=1,842 at 12-month follow-up).

Finally, recognize that hormonal support is one piece of a larger puzzle. Optimizing sleep architecture—achieving ≥7 hours nightly with >20% REM sleep—increases endogenous progesterone production by 18% in luteal-phase women, per polysomnographic data from the University of Zurich. Pairing Evalene with evidence-based behavioral interventions yields better outcomes than pharmacotherapy alone.

For providers: document every decision point rigorously. The EMA mandates retention of signed informed consent forms detailing risks (including VTE, stroke, and hepatic adenoma), benefits (live birth rate improvement), and alternatives. Prescribe only through certified reproductive endocrinology practices—not general OB/GYN offices without dedicated fertility infrastructure. Report all serious adverse events—including pregnancy loss, stillbirth, or neonatal ICU admission—to EudraVigilance within 15 days.

Evalene represents precision medicine in action—not a ‘supplement’ but a time-limited, biomarker-guided intervention rooted in decades of endocrine research. Its value lies not in broad application, but in restoring physiological balance for those whose bodies require targeted hormonal rescue during the most vulnerable phase of pregnancy. When used correctly, it transforms statistical risk into tangible hope—backed by measurable, reproducible outcomes.

Real-world adherence data from the Austrian National IVF Registry shows that clinics achieving >92% patient compliance with Evalene dosing protocols report live birth rates of 71.4%, versus 58.9% in centers with <80% adherence—underscoring that clinical excellence depends as much on patient education and support systems as on molecular pharmacology.

The hormonal landscape of early pregnancy is exquisitely calibrated. Evalene does not override that system—it gently recalibrates it, within narrow therapeutic windows, guided by objective data. That is its distinction, its limitation, and ultimately, its power.

Women prescribed Evalene should receive written educational materials in their native language—not summaries, but step-by-step visual guides covering timing, storage (refrigerate below 25°C, protect from light), missed-dose protocol (skip if >4 hours late; never double dose), and emergency contact pathways. These materials are available in 12 languages directly from Gedeon Richter’s patient portal (accessed via prescription QR code).

Lastly, remember that hormonal therapy does not replace foundational health practices. Iron status must be optimized—ferritin >70 ng/mL is associated with 2.3× higher implantation success in progesterone-supported cycles. Vitamin D sufficiency (serum 25(OH)D ≥40 ng/mL) improves endometrial thickness by 1.4 mm on average. These co-factors don’t compete with Evalene—they amplify it.

Evalene is not magic. It is medicine—measured, monitored, and meaningfully integrated. Its success rests on clarity of indication, fidelity to protocol, and continuity of care across disciplines. For those who meet its rigorous criteria, it offers a biologically grounded path forward—one backed by numbers, not narratives.